Both anatomic (aTSA) and reverse (rTSA) total shoulder arthroplasty are the standard of care for various end-stage degenerative conditions of the glenohumeral joint. Osteoarthritis (OA) is the most common indication for aTSA while Rotator Cuff Tear Arthropathy (CTA) is the most common indication for rTSA. Worldwide, the usage of both aTSA and rTSA has increased significantly due in part, to the predictability of acceptable outcomes achieved with each prosthesis type. The aim of this study is to quantify outcomes using 5 different metrics and compare results achieved for each indication using one platform total shoulder arthroplasty system which utilizes the same humeral component and instrumentation to perform both aTSA or rTSA. 200 patients (70.9 ± 7.3 yrs) were treated by two orthopaedic surgeons using either aTSA or rTSA. 73 patients received aTSA (67.4 ± 8.0 yrs) for treatment of OA (PHF: 64 patients; YM: 9 patients) and 127 patients received a rTSA (72.9 ± 6.1 yrs) for treatment of CTA (PHF: 53 patients; YM: 74 patients). These patients were scored pre-operatively and at latest follow-up using the SST, UCLA, ASES, Constant, and SPADI metrics; active abduction, forward flexion, and external rotation were also measured. The average follow-up for all patients was 31.4 ± 9.7 months (aTSA: 32.5 ± 12.1 months; rTSA: 30.8 ± 8.0 months). A Student's two-tailed, unpaired t-test was used to identify differences in pre-operative, post-operative, and pre-to-post-operative improvements in results, where p < 0.05 denoted a significant difference.Introduction
Methods
